Table 1.
Dalbavancin concentrations of three cardiologic patients.
| Patient | Weight [kg] | Height [cm] | Age [Years] | eGFR [mL/min] |
Albumin [mg/L] | Infection | Pathogen | Dose [mg] |
cmax(d1) [mg/L] | fcmax(d1) [mg/L] * | fcmax(d1) [mg/L] ** | cmin(d8) [mg/L] | fcmin(d8) [mg/L] * | fcmin(d8) [mg/L] ** | fAUC(d8) [mg∙h/L] * | fAUC(d8) [mg∙h/L] ** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 85 | 175 | 60 | d1: 98 d8: 96 |
d1: 46.0 d8: n.a. |
LVAD infection |
S. aureus | 1500 | 278 | 5.4 | 19.5 | 44.9 | 1.3 | 3.1 | 31.2 | 74.4 |
| 2 | 95 | 174 | 58 | d1: 76 d8: 65 |
d1: 44.6 d8: 46.3 |
LVAD infection |
S. aureus | 1500 | 232 | 6.4 | 16.2 | 36.8 | 1.0 | 2.6 | 24.0 | 62.4 |
| 3 | 72 | 176 | 68 | d1: 73 d8: 94 |
d1: 44.3 d8: 44.7 |
LVAD infection |
S. aureus | 1500 | 201 | 6.7 | 14.1 | 23.0 | <1.0 | 1.6 | <24.0 | 38.4 |
cmax peak concentration, cmin trough concentration, d day, eGFR estimated glomular filtration, fc free concentration, LVAD left ventricular assist device, n.a. not available. * Free concentration determined by solid phase extraction using a centrifugal device (Nanosep®, Pall, New York, NY, USA), see also Supplementary Materials Figure S1. ** Free concentration calculated according to approval studies (protein binding of 93%) [4,12].